Enhancement of Anticancer Effects by Combining 5-Fluorouracil with Refametinib in Human Oral Squamous Cell Carcinoma Cell Line
(1) Background: Oral squamous cell carcinoma (OSCC) is a significant health burden worldwide. This study aimed to determine the potentials of Refametinib, an orally bioavailable selective MEK1/2 inhibitor, to increase the effectiveness of 5-Fluorouracil (5-FU), a common cytotoxic drug, in the SCC4 c...
Main Authors: | Po-Chun Chen, Bor-Chyuan Su, Tien-Li Ma, Ying Chui Hong, Yu-Wen Chen, Thi Thuy Tien Vo, Luo-Yun Wu, Tzu-Yu Peng, Ching-Shuen Wang, I-Ta Lee |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-03-01
|
Series: | Applied Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-3417/13/7/4340 |
Similar Items
-
Sanguisorba officinalis L. enhances the 5-fluorouracil sensitivity and overcomes chemoresistance in 5-fluorouracil-resistant colorectal cancer cells via Ras/MEK/ERK and PI3K/Akt pathways
by: Weijia Zhang, et al.
Published: (2023-06-01) -
Prolonged exposure of colon cancer cells to 5-fluorouracil nanoparticles improves its anticancer activity
by: Essam Tawfik, et al.
Published: (2017-02-01) -
Mitomycin and 5‐fluorouracil for second‐line treatment of metastatic squamous cell carcinomas of the anal canal
by: Angélique Saint, et al.
Published: (2019-11-01) -
Matairesinol Induces Mitochondrial Dysfunction and Exerts Synergistic Anticancer Effects with 5-Fluorouracil in Pancreatic Cancer Cells
by: Woonghee Lee, et al.
Published: (2022-07-01) -
The role of NLRP3 inflammasome in 5-fluorouracil resistance of oral squamous cell carcinoma
by: Xiaodong Feng, et al.
Published: (2017-06-01)